Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30858Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Andrews, Miles C | - |
| dc.contributor.author | Vasanthakumar, Ajithkumar | - |
| dc.date | 2022 | - |
| dc.date.accessioned | 2022-09-20T06:45:53Z | - |
| dc.date.available | 2022-09-20T06:45:53Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.citation | Trends in Cancer 2023; 9(1) | en |
| dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/30858 | - |
| dc.description.abstract | Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many patients fail to respond to this therapy or experience side effects. Recently, gut microbiota have emerged as a key determinant of ICB efficacy and toxicity, making manipulation of the microbiome a novel therapeutic strategy with which to improve ICB outcomes. | en |
| dc.language.iso | eng | - |
| dc.title | Gut microbiota - a double-edged sword in cancer immunotherapy. | en |
| dc.type | Journal Article | en |
| dc.identifier.journaltitle | Trends in Cancer | en |
| dc.identifier.affiliation | Department of Medicine - Alfred, Monash University, Melbourne, Victoria, Australia. | en |
| dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute | en |
| dc.identifier.affiliation | La Trobe University, Bundoora, Victoria, Australia | en |
| dc.identifier.doi | 10.1016/j.trecan.2022.08.003 | en |
| dc.type.content | Text | en |
| dc.identifier.pubmedid | 36088249 | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.grantfulltext | none | - |
| item.cerifentitytype | Publications | - |
| item.openairetype | Journal Article | - |
| item.fulltext | No Fulltext | - |
| item.languageiso639-1 | en | - |
| Appears in Collections: | Journal articles | |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.